(Q38578386)

4 September 2017

The safety of calcineurin inhibitors for kidney-transplant patients (English)

1 reference

4 September 2017

2

Lionel Rostaing

1 reference

4 September 2017

Paolo Malvezzi

1

1 reference

PubMed ID

26329325

4 September 2017

language of work or name

English

0 references

publication date

2 September 2015

1 reference

Expert Opinion on Drug Safety

4 September 2017

1 reference

4 September 2017

14

1 reference

4 September 2017

10

1 reference

4 September 2017

1531-1546

1 reference

Cyclosporine: a new immunosuppressive agent for organ transplantation

4 September 2017

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1083974

FK 506: an immunosuppressant for the 1990s?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1083974

The impact of calcineurin inhibitors on graft survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1083974

Calcineurin inhibitor nephrotoxicity: a review and perspective of the evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1083974

Reduced exposure to calcineurin inhibitors in renal transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1083974

Sirolimus: a new promising immunosuppressive drug. Towards a rationale for its use in renal transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1083974

Everolimus: a proliferation signal inhibitor with clinical applications in organ transplantation, oncology, and cardiology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1083974

Everolimus plus reduced-exposure CsA versus mycophenolic acid plus standard-exposure CsA in renal-transplant recipients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1083974

Everolimus leads to a lower risk of BKV viremia than mycophenolic acid in de novo renal transplantation patients: a single-center experience.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1083974

Co-stimulatory blockade with belatacept in kidney transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1083974

Three-year outcomes from BENEFIT, a randomized, active-controlled, parallel-group study in adult kidney transplant recipients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1083974

A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1083974

Risk of posttransplant lymphoproliferative disorder associated with use of belatacept

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1083974

Tissue distribution of calcineurin and its sensitivity to inhibition by cyclosporine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1083974

Cyclosporin A initially as the only immunosuppressant in 34 recipients of cadaveric organs: 32 kidneys, 2 pancreases, and 2 livers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1083974

The PROMISE study: a phase 2b multicenter study of voclosporin (ISA247) versus tacrolimus in de novo kidney transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1083974

Chronic renal failure after transplantation of a nonrenal organ

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1083974

Peptidyl-prolyl cis-trans isomerase is the cyclosporin A-binding protein cyclophilin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1083974

A receptor for the immunosuppressant FK506 is a cis-trans peptidyl-prolyl isomerase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1083974

Nuclear association of a T-cell transcription factor blocked by FK-506 and cyclosporin A

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1083974

Effect of cyclosporine administration on renal hemodynamics in conscious rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1083974

New insights into the pathophysiology of cyclosporine nephrotoxicity: a role of aldosterone.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1083974

Intravenous cyclosporine activates afferent and efferent renal nerves and causes sodium retention in innervated kidneys in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1083974

Follow-up of kidney graft recipients with cyclosporine-associated hemolytic-uremic syndrome and thrombotic microangiopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1083974

Biomarkers of calcineurin inhibitor nephrotoxicity in transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1083974

Chronic cyclosporine nephropathy: the Achilles' heel of immunosuppressive therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1083974

The histopathological changes associated with allograft rejection and drug toxicity in renal transplant recipients maintained on FK506. Clinical significance and comparison with cyclosporine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1083974

Cyclosporine nephrotoxicity: how does it affect renal allograft function and transplant morphology?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1083974

The natural history of chronic allograft nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1083974

Identifying specific causes of kidney allograft loss.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1083974

Expression of TGF-beta and fibrogenic genes in transplant recipients with tacrolimus and cyclosporine nephrotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1083974

Molecular comparison of calcineurin inhibitor-induced fibrogenic responses in protocol renal transplant biopsies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1083974

Cyclosporine-induced interstitial fibrosis and arteriolar TGF-beta expression with preserved renal blood flow.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1083974

Cyclosporine A-induced renal fibrosis: a role for epithelial-mesenchymal transition.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1083974

Fibrosis progression according to epithelial-mesenchymal transition profile: a randomized trial of everolimus versus CsA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1083974

Olmesartan attenuates tacrolimus-induced biochemical and ultrastructural changes in rat kidney tissue.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1083974

Molecular determinants of magnesium homeostasis: insights from human disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1083974

Early and late forms of cyclosporine nephrotoxicity: studies in cardiac transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1083974

No difference in degree of interstitial Sirius red-stained area in serial biopsies from area under concentration-over-time curves-guided cyclosporine versus tacrolimus-treated renal transplant recipients at one year

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1083974

Tacrolimus with mycophenolate mofetil (MMF) or sirolimus vs. cyclosporine with MMF in cardiac transplant patients: 1-year report.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1083974

A comparison of tacrolimus and cyclosporine in liver transplantation: effects on renal function and cardiovascular risk status

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1083974

Influence of immunosuppressive regimens on graft survival and secondary outcomes after kidney transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1083974

Tacrolimus versus ciclosporin as primary immunosuppression for kidney transplant recipients: meta-analysis and meta-regression of randomised trial data

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1083974

Conversion from cyclosporine to tacrolimus in patients at risk for chronic renal allograft failure: 60-month results of the CRAF Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1083974

Calcineurin inhibitor minimization in the Symphony study: observational results 3 years after transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1083974

Results of an international, randomized trial comparing glucose metabolism disorders and outcome with cyclosporine versus tacrolimus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1083974

Calcineurin inhibitors in HLA-identical living related donor kidney transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1083974

Population pharmacokinetics of cyclosporine in kidney and heart transplant recipients and the influence of ethnicity and genetic polymorphisms in the MDR-1, CYP3A4, and CYP3A5 genes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1083974

Differential effect of diarrhea on FK506 versus cyclosporine A trough levels and resultant prevention of allograft rejection in renal transplant recipients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1083974

Cytochrome P450 3A4 and P-glycoprotein activity and assimilation of tacrolimus in transplant patients with persistent diarrhea

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1083974

Cyclosporine microemulsion (Neoral) absorption profiling and sparse-sample predictors during the first 3 months after renal transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1083974

Use of Neoral C monitoring: a European consensus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1083974

Early cyclosporine withdrawal from a sirolimus-based regimen results in better renal allograft survival and renal function at 48 months after transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1083974

Different renal toxicity profiles in the association of cyclosporine and tacrolimus with sirolimus in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1083974

Efficacy and Safety of Early Cyclosporine Conversion to Sirolimus with Continued MMF-Four-Year Results of the Postconcept Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1083974

Considerations in sirolimus use in the early and late post-transplant periods

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1083974

Everolimus (Certican) 12-month safety and efficacy versus mycophenolate mofetil in de novo renal transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1083974

Everolimus with optimized cyclosporine dosing in renal transplant recipients: 6-month safety and efficacy results of two randomized studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1083974

The effect of everolimus versus mycophenolate upon proteinuria following kidney transplant and relationship to graft outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1083974

Donor-specific HLA antibodies in a cohort comparing everolimus with cyclosporine after kidney transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1083974

Five-year outcomes in kidney transplant patients converted from cyclosporine to everolimus: the randomized ZEUS study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1083974

Calcineurin inhibitor-sparing regimens based on mycophenolic acid after kidney transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1083974

Diabetes mellitus after kidney transplantation: a French multicentre observational study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1083974

Diabetes mellitus after kidney transplantation in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1083974

Effect of different immunosuppressive regimens on the evolution of distinct metabolic parameters: evidence from the Symphony study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1083974

Calcineurin/NFAT signaling in the beta-cell: From diabetes to new therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1083974

Independent effects of cyclosporine and prednisone on posttransplant hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1083974

Improved cardiovascular risk profile and renal function in renal transplant patients after randomized conversion from cyclosporine to tacrolimus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1083974

Involvement of glial cells in cyclosporine-increased permeability of brain endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1083974

Drug-induced gingival hyperplasia in transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1083974

Poor oral hygiene enhances gingival overgrowth caused by calcineurin inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1083974

Tacrolimus-induced alopecia in female kidney-pancreas transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1083974

Infection in organ-transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1083974

Canadian society of transplantation consensus workshop on cytomegalovirus management in solid organ transplantation final report

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1083974

Cytomegalovirus infection and new-onset post-transplant diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1083974

Cytomegalovirus risk factors in renal transplantation with modern immunosuppression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1083974

Everolimus-treated renal transplant recipients have a more robust CMV-specific CD8+ T-cell response compared with cyclosporine- or mycophenolate-treated patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1083974

Polyomavirus BK replication in de novo kidney transplant patients receiving tacrolimus or cyclosporine: a prospective, randomized, multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1083974

Risk factors for BK virus infection in the era of therapeutic drug monitoring

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1083974

BK viremia and polyomavirus nephropathy in 352 kidney transplants; risk factors and potential role of mTOR inhibition.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1083974

Posttransplantation lymphoproliferative disorder in patients under primary tacrolimus (FK 506) immunosuppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1083974

Determination of risk factors for Epstein-Barr virus-associated posttransplant lymphoproliferative disorder in pediatric liver transplant recipients using objective case ascertainment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1083974

Risk factors and prognosis in T-cell posttransplantation lymphoproliferative diseases: reevaluation of 163 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1083974

Spectrum of cancer risk among US solid organ transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1083974

Cyclosporine induces cancer progression by a cell-autonomous mechanism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1083974

Skin cancer in organ transplant recipients: effects of immunosuppressive medications on DNA repair

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1083974

Cyclosporin A, but not everolimus, inhibits DNA repair mediated by calcineurin: implications for tumorigenesis under immunosuppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1083974

Effect of long-term immunosuppression in kidney-graft recipients on cancer incidence: randomised comparison of two cyclosporin regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1083974

Sirolimus for Kaposi's sarcoma in renal-transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1083974

Maintenance immunosuppression with target-of-rapamycin inhibitors is associated with a reduced incidence of de novo malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1083974

Hyperuricemia in pediatric renal transplant recipients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1083974

New-onset gout after kidney transplantation: incidence, risk factors and implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1083974

Cyclosporin: an updated review of the pharmacokinetic properties, clinical efficacy and tolerability of a microemulsion-based formulation (neoral)1 in organ transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1083974

Drug interactions with tacrolimus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1083974

Randomized Trial of Everolimus-Facilitated Calcineurin Inhibitor Minimization Over 24 Months in Renal Transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1083974

10.1517/14740338.2015.1083974

21 January 2018

Identifiers

DOI

1 reference

4 September 2017

1 reference

PubMed ID

26329325